Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
The FDA has approved Scholar Rock's Isembyld (apitegromab) — the first muscle-targeted therapy for spinal muscular atrophy (SMA). Designed for patients already on existing SMA treatments, it works by blocking myostatin to boost muscle mass and strength. The approval marks Scholar Rock's first-ever regulatory green light and puts it in direct competition with Biogen, Novartis, and Roche.
The FDA just handed Scholar Rock its first-ever drug approval — and it's a significant milestone. Isembyld (apitegromab), an injectable therapy for spinal muscular atrophy (SMA), becomes the first muscle-targeted treatment designed to improve motor function in both adults and children already receiving existing SMA therapies. SMA is a rare genetic disorder affecting roughly 10,000 Americans, causing progressive muscle weakness and difficulties with movement, breathing, and swallowing.
What makes Isembyld stand out is its mechanism: it selectively blocks myostatin, a protein that naturally limits muscle growth, with the goal of increasing muscle mass and strength on top of what current treatments already provide. The approval was backed by late-stage trial data showing significant motor function improvements versus placebo.
By the Numbers:
Why it matters: Isembyld fills a critical gap — it's the first therapy targeting the muscle itself, rather than the underlying genetic defect, offering an add-on option for patients who still struggle with weakness despite existing treatments. Scholar Rock is also exploring its use in obesity-related muscle loss, signaling broader potential ahead.
